Compare Stocks → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKCAOTCMKTS:BLUSFOTCMKTS:CYDYNASDAQ:DRNANYSE:MYOV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/ABLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCYDYCytoDyn$0.15$0.17$0.13▼$0.42$144.96M0.162.63 million shs420,675 shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%BLUSFBELLUS Health0.00%0.00%0.00%0.00%+2.15%CYDYCytoDyn-1.00%+0.34%-11.61%-15.19%-48.79%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside himMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKCAAkcea TherapeuticsN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14BLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CYDYCytoDyn$270K536.89N/AN/A($0.12) per share-1.22DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/ABLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACYDYCytoDyn-$79.82M-$0.05N/A∞N/AN/AN/A-478.47%N/ADRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AMYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/ALatest DRNA, BLUSF, AKCA, CYDY, and MYOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/15/2024Q3 2024CYDYCytoDynN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKCAAkcea TherapeuticsN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKCAAkcea TherapeuticsN/A12.1711.78BLUSFBELLUS HealthN/A13.8713.87CYDYCytoDynN/A0.080.08DRNADicerna PharmaceuticalsN/A2.462.46MYOVMyovant SciencesN/A1.571.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKCAAkcea Therapeutics19.27%BLUSFBELLUS HealthN/ACYDYCytoDyn5.06%DRNADicerna Pharmaceuticals78.91%MYOVMyovant Sciences30.62%Insider OwnershipCompanyInsider OwnershipAKCAAkcea Therapeutics1.50%BLUSFBELLUS Health24.17%CYDYCytoDyn0.71%DRNADicerna Pharmaceuticals10.20%MYOVMyovant Sciences1.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCYDYCytoDyn12992.87 million985.82 millionNot OptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableDRNA, BLUSF, AKCA, CYDY, and MYOV HeadlinesSourceHeadlineSalvage RT After Prostatectomy Prevails in Long-Term Comparison With Adjuvant RTmedpagetoday.com - April 19 at 7:59 PMWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugsuk.finance.yahoo.com - April 18 at 9:20 AMResearchers discover urine-based test to detect head and neck cancereurekalert.org - April 16 at 2:43 PMSocial Sciences & Interdisciplinary Studiescsus.edu - April 4 at 11:01 PMRoivant reveals positive immune drug data, share buyback plansbiopharmadive.com - April 2 at 3:38 PMComputer Science on Campusbc.edu - March 15 at 9:42 AMExposure to Teratogenic Medicine Common Before Prenatal Caremedpagetoday.com - February 6 at 9:50 AM2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout Yearforbes.com - January 15 at 2:17 PMGlobal $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and Regionfinance.yahoo.com - January 11 at 8:54 PMReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executivesfinance.yahoo.com - January 3 at 9:54 AMVivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...dailymail.co.uk - December 28 at 3:21 PMSumitomo Pharma CEO Myrtle Potter Focuses On Leading By Examplehealthleadersmedia.com - December 22 at 9:52 AMMetastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsightfinance.yahoo.com - December 8 at 9:34 AMDespite Effective Therapies, Fibroid Care Still Lackingmedscape.com - November 27 at 4:27 PMNCCN Announces Funding for Advanced Prostate Cancer Research Projectsmarkets.businessinsider.com - November 21 at 9:43 AMBlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in ...br.advfn.com - November 14 at 7:11 PMNews - Orgovyxthepharmaletter.com - October 24 at 3:11 PMNews - Myovant Sciencesthepharmaletter.com - October 24 at 3:11 PMMyovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoingsbarrons.com - October 22 at 10:14 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant ...bakersfield.com - October 3 at 7:01 PMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVbenzinga.com - September 26 at 8:57 PMSumitomo Sued Over Skadden’s Alleged Conflicts in Myovant Mergernews.bloomberglaw.com - September 14 at 3:31 PM4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business Chiefmarketwatch.com - September 12 at 6:07 PMHormone Sensitive Advanced Prostate Cancer Treatment Market Set to Soar at 7.2% CAGR, Exceeding US$ 24.94 Billion by 2033 | Says FMIfmiblog.com - September 8 at 6:10 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.BELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.CytoDynOTCMKTS:CYDYCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Dicerna PharmaceuticalsNASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Myovant SciencesNYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.